| Previous Close | 1.3 |
| Open | 1.4 |
| Day High | 1.42 |
| Day Low | 1.08 |
| 52-Week High | 1.81 |
| 52-Week Low | 0.64 |
| Volume | 4.48M |
| Average Volume | 943,025 |
| Market Cap | 116.62M |
| PE | -3.77 |
| EPS | -0.3 |
| Moving Average 50 Days | 1.26 |
| Moving Average 200 Days | 1.07 |
| Change | -0.17 |
MaxCyte unveils ExPERT DTx™, a 96-well electroporation platform to accelerate discovery
GlobeNewswire Inc.
Feb 24, 2026 1:05 PM GMT
ROCKVILLE, Md., Feb. 24, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cel
MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026
GlobeNewswire Inc.
Feb 23, 2026 9:05 PM GMT
ROCKVILLE, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cel
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results
GlobeNewswire Inc.
Jan 12, 2026 1:05 PM GMT
ROCKVILLE, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-gen